Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemnifosbuvir PK in Hepatic Impairment
NCT05724693Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Jan 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bemnifosbuvir in coronavirus disease 2019 (COVID-19) and hepatitis C (HCV) (5 arms), sponsored by Atea Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at Day 1 and Area Under the Plasma Concentration-Time Curve at Day 1. Started Jan 2023; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)hepatitis C (HCV)
Beyond the preview
Go deeper on NCT05724693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05724693.